We use cookies for a better user experience. Read our Privacy Policy

I Agree

Glioma Treatment Market

Glioma Treatment Market (Type: Low-grade and High-grade) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2022-2031

Glioma Treatment Market Outlook 2031

  • The global glioma treatment market was valued at US$ 4.39 Bn in 2021
  • The global market is projected to grow at a CAGR of 5.7% from 2022 to 2031
  • The global glioma treatment market is anticipated to reach more than US$ 7.51 Bn by 2031

Analysts’ Viewpoint on Glioma Treatment Market Scenario

Surge in number of surgeries performed across the globe and major technological innovations in radiation therapy for glioma, molecular therapies, chemotherapy, and targeted therapies are driving the global glioma treatment market. Furthermore, notable growth potential in emerging countries such as India, South Korea, and Brazil is projected to boost the glioma treatment market during the forecast period. However, less survival rate and lack of awareness are estimated to hamper the global market in the near future. Nevertheless, increase in investments by public & private organizations and entry of various startups into the glioma treatment market are likely to lead to positive sentiment among patients toward effective treatment.

glioma treatment market

Global Glioma Treatment Market Introduction

Glioma is a condition that covers a broad category of brain and spinal cord tumors that affect the glial cells in the brain. Glioma can affect brain function and can be fatal depending on its location and severity of the tumor. Different types of gliomas are astrocytoma, brain stem gliomas, ependymomas, mixed gliomas (oligo-astrocytomas), oligodendrogliomas, and optic pathway gliomas. Common glioma symptoms include headache, nausea, vomiting, confusion, and decline in brain function. Various therapeutic options are available for the treatment of glioma. These include radiation therapy for glioma, chemotherapy, glioma targeted therapy, and surgery. Late stage clinical pipeline drugs can be effective treatment options for glioma.

Approval of late stage pipeline drug designation to certain molecules for the treatment of glioma is a major factor that is likely to drive the global glioma diagnosis and treatment market. For instance, on December 05, 2019, the U.S. FDA and European Medicines Agency granted orphan drug designation to Adastra Pharmaceuticals drug zotiraciclib, a multikinase inhibitor. This drug is being evaluated in two phase 1b clinical studies of patients with glioblastoma ‒ the most common glioma histology for the treatment of glioma. Rise in prevalence of brain cancer and increase in awareness regarding various types of gliomas are also fueling the global glioma treatment market. Moreover, strategic alliances for the development of glioma therapeutics products and increase in exposure of humans to radiation in the last few years, which leads to higher incidence of brain cancer, are some of the key factors propelling the global glioma therapy market.

Request a sample to get extensive insights into the Glioma Treatment Market

COVID-19 Impact on Global Glioma Treatment Market

The outbreak of COVID-19 has had a negative effect on the global glioma treatment market. Governments of affected countries gave instructions for the postponement of non-essential surgeries and patient visits. Surgical neuro-oncology is a specialty that created a dilemma in continuing surgical care during the pandemic. Several ICU facilities, such as ventilators, personal protective equipment, and medical staff, were rerouted to COVID-19 cases, prompting the suspension of surgical neuro-oncology services during the pandemic. Instability in the provision of adequate medical care to critically-ill cancer patients was witnessed during the pandemic. Additionally, glioblastoma patients are vulnerable to the COVID-19 infection, which led to postponement of treatments and surgeries. Thus, there was a decrease in Y-o-Y growth due to postponed brain surgeries in hospitals and ambulatory surgical centers during the COVID-19 outbreak.

Rise in Incidence and Prevalence of High Grade Gliomas to Drive Market

In terms of type, the global glioma treatment market has been divided into low-grade gliomas and high-grade gliomas. High-grade gliomas is anticipated to be a highly lucrative segment in the near future due to the availability of more options for diagnosis and treatment of glioma tumor of this grade. High-grade gliomas are highly severe tumors and largely occur in children and adults. Various factors such as frequent radiation therapies, improper surgeries of the brain, and multiple therapies are expected to drive the market. Manufacturers are emphasizing on the use of innovative technologies, which is projected to fuel the segment in the near future. For instance, ASCO 2022 would get fresh clinical data on the usage of Kiyatec's ex vivo 3D cell culture technique for high-grade glioma. Furthermore, rise in prevalence and incidence of high-grade gliomas is driving the market. High-grade glioma is one of the frequently diagnosed primary brain tumors. According to the National Library of Medicine, the incidence rate of high-grade glioma is about 5.8 males and 4.1 females per 100,000 people per year.

Request a custom report on Glioma Treatment Market

Surgery, the First Step in Treatment of Most Gliomas

Based on treatment, the surgery segment dominated the global glioma treatment market in 2021. This trend is projected to continue during the forecast period. Surgery to remove as many tumors as possible is usually the first step in treating most gliomas. In some cases, gliomas are small and can be easily removed from the surrounding healthy brain tissue, allowing for complete surgical removal. Moreover, presence of reimbursement policies that encourage healthcare providers to maintain quality infrastructure is expected to boost the surgery segment. Thus, increase in success rate of surgeries and reimbursement policies is expected to drive the surgery segment. Additionally, rise in number of surgical procedures for the treatment of glioma in growing economies, including China and India, is boosting the segment. Governments of China and India have increased their healthcare spend, which in turn is augmenting the admission of patients in hospitals.

Regional Outlook of Global Glioma Treatment Market

In terms of region, North America dominated the global glioma treatment market in 2021. This can be ascribed to the rise in approval of new products for glioma treatment, higher prevalence of brain tumor cases, growing exposure of population to radiation, and presence of major companies in the region. For instance, according to stats by the American Society of Clinical Oncology (ASCO), an estimated 23,820 adults in the U.S. were diagnosed with primary cancerous tumors of the brain and spinal cord in 2018. Brain tumors accounted for 85% to 90% of all primary CNS tumors.

The market in Asia Pacific is expected to be highly lucrative during the forecast period due to the launch of approved products in the region in the latter half of the forecast period, higher geriatric population, increase in number of patients with cancer, and rise in awareness regarding diseases & treatment.

Analysis of Key Players in Global Glioma Treatment Market

This report includes vital information about the key players operating in the global glioma treatment market. Key players are focusing on strategies such as new product launches, divestiture, mergers & acquisitions (M&A), and partnerships to consolidate their position in the market. Sun Pharmaceutical Industries Ltd., Amgen, Inc., Teva Pharmaceutical Industries Ltd, Bristol-Myers Squibb Company, Pfizer, Inc., Merck KGaA, and F. Hoffmann-La Roche Ltd. are the prominent players operating in the global glioma treatment market.

Key Developments in Global Glioma Treatment Market

  • In June 2022, Novartis, a leading biopharmaceutical company, announced that ‘Tafinlar’ and Mekinist significantly improved the efficacy in patients aged 1 to 17 years with BRAF V600 pediartric low-grade glioma, which is the first systematic treatment as compared to chemotherapy
  • In June 2022, VBI Vaccine, a renowned biopharmaceutical company, received U.S. FDA Orphan Drug Designation for ‘VBI-1901’ for the treatment of glioblastoma
  • In May 2022, according to the study published by BMC cancer, the University of Surrey showed that a chain of amino acids is effective in targeting and inhibiting the function of a family of genes responsible for the growth of Glioblastoma Multiforme (GBM)
  • In April 2022, CNS Pharmaceuticals announced plans to commence the pivotal trial of ‘Berubin’ to treat recurrent GBM
  • On February 10, 2022, Theragnostics announced that its novel radio therapeutic I-123 PARPi therapeutic agent for the treatment of GBM had been awarded the U.K.'s Medicines & Healthcare Products Regulatory Agency approval for the treatment of primary & recurrent glioblastoma multiforme
  • In January 2022, ITM Isotope Technologies Munich SE, a Germany-based pharmaceutical company, entered into a cooperation agreement with Helmholtz Zentrum München, the German Research Center for Environmental Health, for the clinical development of radiopharmaceutical therapy to treat GBM
  • In December 2021, ICAD Technology announced that the first recurrent glioblastoma tumor was treated with Xoft Brain IORT in the U.S.
  • In October 2021, the FDA granted a breakthrough designation to Alpha Tau’s device ‘Alpha DaRT’ for the treatment of GBM

Each of these players has been profiled in the glioma treatment market report based on parameters such as company overview, financial overview, business strategies, product portfolio, business segments, and recent developments.

Global Glioma treatment Market Snapshot

Attribute

Detail

Market Size Value in 2021

US$ 4.39 Bn

Market Forecast Value in 2031

More than US$ 7.51 Bn

Compound Annual Growth Rate (CAGR)

5.7%

Forecast Period

2022–2031

Historical Data Available for

2017–2021

Quantitative Units

US$ Bn for Value

Market Analysis

It includes segment analysis as well as regional level analysis. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, and parent industry overview.

Competition Landscape

  • Market share analysis/ranking by company (2021)
  • Company profiles section includes overview, product portfolio, sales footprint, key subsidiaries or distributors, strategy & recent developments, and key financials

Format

Electronic (PDF) + Excel

Market Segmentation

  • Type
    • Low-grade
      • grade I
      • grade II
    • High-grade
      • grade III
      • grade IV
  • Treatment
    • Surgery
    • Radiation Therapy
    • Chemotherapy
    • Targeted Drug Therapy
    • Others

Regions Covered

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

Countries Covered

  • U.S.
  • Canada
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • China
  • India
  • Japan
  • Australia & New Zealand
  • Brazil
  • Mexico
  • GCC Countries
  • South Africa

Companies Profiled

  • Sun Pharmaceutical Industries Ltd.
  • Amgen, Inc.
  • Teva Pharmaceutical Industries Ltd
  • Bristol-Myers Squibb Company
  • Pfizer, Inc.
  • Merck KGaA
  • F. Hoffmann-La Roche Ltd

Customization Scope

Available upon request

Pricing

Available upon request

Interested in this report?
Get a FREE sample now!

Get Free Sample

*Get Sample Report (PDF) sent to your email within minutes

Frequently Asked Questions

How big was the global glioma treatment market in 2021?

The global glioma treatment market was valued at US$ 4.39 Bn in 2021.

How big will be the global glioma treatment market in 2031?

The global glioma treatment market is projected to reach more than US$ 7.51 Bn by 2031.

What will be the CAGR of the global glioma treatment market during the forecast period (2022–2031)?

The global glioma treatment market is anticipated to grow at a CAGR of 5.7% from 2022 to 2031.

Which are the prominent trends that affect market growth?

Increase in drug approval for glioma treatment is driving the global glioma treatment market.

Which region will account for major share of the global market during the forecast period?

North America is expected to account for major share of the global glioma treatment market during the forecast period.

Who are the prominent players in the global glioma treatment market?

Sun Pharmaceutical Industries Ltd., Amgen, Inc., Teva Pharmaceutical Industries Ltd, Bristol-Myers Squibb Company, Pfizer, Inc., Merck KGaA, and F. Hoffmann-La Roche Ltd.

1. Preface

    1.1. Market Definition and Scope

    1.2. Market Segmentation

    1.3. Key Research Objectives

    1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary : Global Glioma Treatment Market

4. Market Overview

    4.1. Introduction

        4.1.1. Definition

        4.1.2. Industry Evolution / Developments

    4.2. Overview

    4.3. Market Dynamics

        4.3.1. Drivers

        4.3.2. Restraints

        4.3.3. Opportunities

    4.4. Global Glioma Treatment Market Analysis and Forecasts, 2017‒2031

5. Key Insights

    5.1. Key Industry Events (Mergers & Acquisitions, Product Launches, Partnerships)

    5.2. Pipeline Analysis

    5.3. Low Grade Glioma: Overview

    5.4. Disease Prevalence Rate & Incidence Rate Globally

    5.5. Covid-19 Pandemic Impact on the Industry

6. Global Glioma Treatment Market Analysis and Forecast, by Type

    6.1. Introduction & Definition

    6.2. Key Findings / Developments

    6.3. Market Value Forecast, by Type, 2017‒2031

        6.3.1. Low-Grade

            6.3.1.1. grade I

            6.3.1.2. grade II

        6.3.2. High-grade

            6.3.2.1. grade III

            6.3.2.2. grade IV

    6.4. Market Attractiveness, by Type

7. Global Glioma Treatment Market Analysis and Forecast, by Treatment

    7.1. Introduction & Definition

    7.2. Key Findings / Developments

    7.3. Market Value Forecast, by Treatment, 2017‒2031

        7.3.1. Surgery

        7.3.2. Radiation Therapy

        7.3.3. Chemotherapy

        7.3.4. Targeted Drug Therapy

        7.3.5. Others

    7.4. Market Attractiveness, by Treatment

8. Global Glioma Treatment Market Analysis and Forecast, by Region

    8.1. Key Findings

    8.2. Market Value Forecast, by Region

        8.2.1. North America

        8.2.2. Europe

        8.2.3. Asia Pacific

        8.2.4. Latin America

        8.2.5. Middle East & Africa

    8.3. Market Attractiveness, by Region

9. North America Glioma Treatment Market Analysis and Forecast

    9.1. Introduction

        9.1.1. Key Findings

    9.2. Market Value Forecast, by Type, 2017‒2031

        9.2.1. Low-Grade

            9.2.1.1. grade I

            9.2.1.2. grade II

        9.2.2. High-grade

            9.2.2.1. grade III

            9.2.2.2. grade IV

    9.3. Market Value Forecast, by Treatment, 2017‒2031

        9.3.1. Surgery

        9.3.2. Radiation Therapy

        9.3.3. Chemotherapy

        9.3.4. Targeted Drug Therapy

        9.3.5. Others

    9.4. Market Value Forecast, by Country, 2017‒2031

        9.4.1. U.S.

        9.4.2. Canada

    9.5. Market Attractiveness Analysis

        9.5.1. By Type

        9.5.2. By Treatment

        9.5.3. By Country

10. Europe Glioma Treatment Market Analysis and Forecast

    10.1. Introduction

        10.1.1. Key Findings

    10.2. Market Value Forecast, by Type, 2017‒2031

        10.2.1. Low-Grade

            10.2.1.1. grade I

            10.2.1.2. grade II

        10.2.2. High-grade

            10.2.2.1. grade III

            10.2.2.2. grade IV

    10.3. Market Value Forecast, by Treatment, 2017‒2031

        10.3.1. Surgery

        10.3.2. Radiation Therapy

        10.3.3. Chemotherapy

        10.3.4. Targeted Drug Therapy

        10.3.5. Others

    10.4. Market Value Forecast, by Country/Sub-region, 2017‒2031

        10.4.1. Germany

        10.4.2. U.K.

        10.4.3. France

        10.4.4. Italy

        10.4.5. Spain

        10.4.6. Rest of Europe

    10.5. Market Attractiveness Analysis

        10.5.1. By Type

        10.5.2. By Treatment

        10.5.3. By Country/Sub-region

11. Asia Pacific Glioma Treatment Market Analysis and Forecast

    11.1. Introduction

        11.1.1. Key Findings

    11.2. Market Value Forecast, by Type, 2017‒2031

        11.2.1. Low-Grade

            11.2.1.1. grade I

            11.2.1.2. grade II

        11.2.2. High-grade

            11.2.2.1. grade III

            11.2.2.2. grade IV

    11.3. Market Value Forecast, by Treatment, 2017‒2031

        11.3.1. Surgery

        11.3.2. Radiation Therapy

        11.3.3. Chemotherapy

        11.3.4. Targeted Drug Therapy

        11.3.5. Others

    11.4. Market Value Forecast, by Country/Sub-region, 2017‒2031

        11.4.1. China

        11.4.2. Japan

        11.4.3. India

        11.4.4. Australia & New Zealand

        11.4.5. Rest of Asia Pacific

    11.5. Market Attractiveness Analysis

        11.5.1. By Type

        11.5.2. By Treatment

        11.5.3. By Country/Sub-region

12. Latin America Glioma Treatment Market Analysis and Forecast

    12.1. Introduction

        12.1.1. Key Findings

    12.2. Market Value Forecast, by Type, 2017‒2031

        12.2.1. Low-Grade

            12.2.1.1. grade I

            12.2.1.2. grade II

        12.2.2. High-grade

            12.2.2.1. grade III

            12.2.2.2. grade IV

    12.3. Market Value Forecast, by Treatment, 2017‒2031

        12.3.1. Surgery

        12.3.2. Radiation Therapy

        12.3.3. Chemotherapy

        12.3.4. Targeted Drug Therapy

        12.3.5. Others

    12.4. Market Value Forecast, by Country/Sub-region, 2017‒2031

        12.4.1. Brazil

        12.4.2. Mexico

        12.4.3. Rest of Latin America

    12.5. Market Attractiveness Analysis

        12.5.1. By Type

        12.5.2. By Treatment

        12.5.3. By Country/Sub-region

13. Middle East & Africa Glioma Treatment Market Analysis and Forecast

    13.1. Introduction

        13.1.1. Key Findings

    13.2. Market Value Forecast, by Type, 2017‒2031

        13.2.1. Low-Grade

            13.2.1.1. grade I

            13.2.1.2. grade II

        13.2.2. High-grade

            13.2.2.1. grade III

            13.2.2.2. grade IV

    13.3. Market Value Forecast, by Treatment, 2017‒2031

        13.3.1. Surgery

        13.3.2. Radiation Therapy

        13.3.3. Chemotherapy

        13.3.4. Targeted Drug Therapy

        13.3.5. Others

    13.4. Market Value Forecast, by Country/Sub-region, 2017‒2031

        13.4.1. GCC Countries

        13.4.2. South Africa

        13.4.3. Rest of Middle East & Africa

    13.5. Market Attractiveness Analysis

        13.5.1. By Type

        13.5.2. By Treatment

        13.5.3. By Country/Sub-region

14. Competition Landscape

    14.1. Market Player – Competition Matrix (By Tier and Size of companies)

    14.2. Market Share Analysis By Company (2021)

    14.3. Company Profiles

        14.3.1. Bristol-Myers Squibb Company

            14.3.1.1. Company Overview

            14.3.1.2. Company Financials

            14.3.1.3. Growth Strategies

            14.3.1.4. SWOT Analysis

        14.3.2. Genentech, Inc. (F. Hoffmann-La Roche Ltd.

            14.3.2.1. Company Overview

            14.3.2.2. Company Financials

            14.3.2.3. Growth Strategies

            14.3.2.4. SWOT Analysis

        14.3.3. Pfizer, Inc.

            14.3.3.1. Company Overview

            14.3.3.2. Company Financials

            14.3.3.3. Growth Strategies

            14.3.3.4. SWOT Analysis

        14.3.4. Merck & Co., Inc

            14.3.4.1. Company Overview

            14.3.4.2. Company Financials

            14.3.4.3. Growth Strategies

            14.3.4.4. SWOT Analysis

        14.3.5. Teva Pharmaceutical Industries Ltd

            14.3.5.1. Company Overview

            14.3.5.2. Company Financials

            14.3.5.3. Growth Strategies

            14.3.5.4. SWOT Analysis

        14.3.6. Sun Pharmaceutical Industries Ltd.

            14.3.6.1. Company Overview

            14.3.6.2. Company Financials

            14.3.6.3. Growth Strategies

            14.3.6.4. SWOT Analysis

        14.3.7. Amgen, Inc.

            14.3.7.1. Company Overview

            14.3.7.2. Company Financials

            14.3.7.3. Growth Strategies

            14.3.7.4. SWOT Analysis

        14.3.8. Other prominent players

            14.3.8.1. Company Overview

            14.3.8.2. Company Financials

            14.3.8.3. Growth Strategies

            14.3.8.4. SWOT Analysis

*Note: Financial details for companies that do not report this information in public domain might not be captured

List of Tables

Table 01: Global Glioma Treatment Market Value (US$ Mn) Forecasts, by Type, 2017–2031

Table 02: Global Glioma Treatment Market Value (US$ Mn) Forecast, by High-grade, 2017–2031

Table 03: Global Glioma Treatment Market Value (US$ Mn) Forecast, by Low-grade , 2017–2031

Table 04: Global Glioma Treatment Market Value (US$ Mn) Forecast, by Treatment, 2017–2031

Table 05: Global Glioma Treatment Market Value (US$ Mn) Forecast, by Region, 2017–2031

Table 06: North America Glioma Treatment Market Value (US$ Mn) Forecast, by Country, 2017–2031

Table 07: North America Glioma Treatment Market Value (US$ Mn) Forecast, by Type, 2017–2031

Table 08: North America Glioma Treatment Market Value (US$ Mn) Forecast, by High-grade, 2017–2031

Table 09: North America Glioma Treatment Market Value (US$ Mn) Forecast, by Low-grade, 2017–2031

Table 10: North America Glioma Treatment Market Value (US$ Mn) Forecast, by Treatment, 2017–2031

Table 11: Europe Glioma Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 12: Europe Glioma Treatment Market Value (US$ Mn) Forecast, by Type, 2017–2031

Table 13: Europe Glioma Treatment Market Value (US$ Mn) Forecast, by High-grade, 2017–2031

Table 14: Europe Glioma Treatment Market Value (US$ Mn) Forecast, by Low-grade, 2017–2031

Table 15: Europe Glioma Treatment Market Value (US$ Mn) Forecast, by Treatment, 2017–2031

Table 16: Asia Pacific Glioma Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031 

Table 17: Asia Pacific Glioma Treatment Market Value (US$ Mn) Forecast, by Type, 2017–2031

Table 18: Asia Pacific Glioma Treatment Market Analysis and Value (US$ Mn) Forecast, by High-grade, 2017–2031

Table 19: Asia Pacific Glioma Treatment Market Value (US$ Mn) Forecast, by Low-grade, 2017–2031

Table 20: Asia Pacific Glioma Treatment Market Value (US$ Mn) Forecast, by Treatment, 2017–2031

Table 21: Latin America Glioma Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 22: Latin America Glioma Treatment Market Value (US$ Mn) Forecast, by Type, 2017–2031

Table 23: Latin America Glioma Treatment Market and Value (US$ Mn) Forecast, by High-grade, 2017–2031

Table 24: Latin-America Glioma Treatment Market Value (US$ Mn) Forecast, by Low-grade , 2017–2031

Table 25: Latin America Glioma Treatment Market Value (US$ Mn) Forecast, by Treatment, 2017–2031

Table 26: Middle East & Africa Glioma Treatment Market Analysis and Forecast, by Country/Sub-region, 2017–2031

Table 27: Middle East & Africa Glioma Treatment Market Analysis and Forecast, by Type, 2017–2031

Table 28: Middle East & Africa Glioma Treatment Market Analysis and Forecast, by High-grade, 2017–2031

Table 29: Middle East & Africa Glioma Treatment Market Analysis and Forecast, by Low-grade, 2017–2031

Table 30: Middle East & Africa Glioma Treatment Market Analysis and Forecast, by Treatment, 2017–2031

List of Figures

Figure 01: Global Glioma Treatment Market Value (US$ Mn) Forecast, 2017–2031

Figure 02: Global Glioma Treatment Market Value Share, by Type, 2021

Figure 03: Global Glioma Treatment Market Value Share, by Treatment, 2021

Figure 04: Global Glioma Treatment Market Value Share, by Region, 2021

Figure 05: 5-year Relative Survival Rate

Figure 06: Global Glioma Treatment Market, by Type, 2021 and 2031

Figure 07: Global Glioma Treatment Market Attractiveness Analysis, by Type, 2022–2031

Figure 08: Global Glioma Treatment Market (US$ Mn), by High-grade, 2017–2031

Figure 09: Global Glioma Treatment Market (US$ Mn), by Low-grade , 2017–2031

Figure 10: Global Glioma Treatment Market, by Treatment, 2021 and 2031

Figure 11: Global Glioma Treatment Market Attractiveness Analysis, by Treatment, 2022–2031

Figure 12: Global Glioma Treatment Market (US$ Mn), by Surgery, 2017–2031

Figure 13: Global Glioma Treatment Market (US$ Mn), by Radiation Therapy , 2017–2031

Figure 14: Global Glioma Treatment Market (US$ Mn), by Chemotherapy, 2017–2031

Figure 15: Global Glioma Treatment Market (US$ Mn), by Targeted Drug therapy, 2017–2031 

Figure 16: Global Glioma Treatment Market (US$ Mn), by Others, 2017–2031

Figure 17: Global Glioma Treatment Market, by Region, 2021 and 2031

Figure 18: Global Glioma Treatment Market Attractiveness Analysis, by Region, 2022–2031

Figure 19: North America Glioma Treatment Market Value (US$ Mn) Forecast, 2017–2031

Figure 20: North America Glioma Treatment Market, By Country, 2021 And 2031

Figure 21: North America Glioma Treatment Market Attractiveness Analysis, by Country, 2022–2031

Figure 22: North America Glioma Treatment Market, by Type, 2021 and 2031

Figure 23: North America Glioma Treatment Market Attractiveness Analysis, by Type, 2022–2031

Figure 24: North America Glioma Treatment Market, by Treatment, 2021 and 2031

Figure 25: North America Glioma Treatment Market Attractiveness Analysis, by Treatment, 2022–2031

Figure 26: Europe Glioma Treatment Market Value (US$ Mn) Forecast, 2017–2031

Figure 27: Europe Glioma Treatment Market, by Country/Sub-region, 2021 and 2031

Figure 28: Europe Glioma Treatment Market Attractiveness Analysis, by Country/Sub-region, 2022–2031

Figure 29: Europe Glioma Treatment Market, by Type, 2021 and 2031

Figure 30: Europe Glioma Treatment Market Attractiveness Analysis, by Type, 2022–2031

Figure 31: Europe Glioma Treatment Market, by Treatment, 2021 and 2031

Figure 32: Europe Glioma Treatment Market Attractiveness Analysis, by Treatment, 2022–2031

Figure 33: Asia Pacific Glioma Treatment Market Value (US$ Mn) Forecast, 2017–2031

Figure 34: Asia Pacific Glioma Treatment Market, by Country/Sub-region, 2021 and 2031

Figure 35: Asia Pacific Glioma Treatment Market Attractiveness Analysis, by Country/Sub-region, 2022–2031

Figure 36: Asia Pacific Glioma Treatment Market, by Type, 2021 and 2031

Figure 37: Asia Pacific Glioma Treatment Market Attractiveness Analysis, by Type, 2022–2031

Figure 38:Asia Pacific Glioma Treatment Market, by Treatment, 2021 and 2031

Figure 39: Asia Pacific Glioma Treatment Market Attractiveness Analysis, by Treatment, 2022–2031

Figure 40: Latin America Glioma Treatment Market Value (US$ Mn) Forecast, 2017–2031

Figure 41: Latin America Treatment Market, by Country/Sub-region, 2021 and 2031

Figure 42: Latin America Treatment Market Attractiveness Analysis, by Country/Sub-region, 2022–2031

Figure 43: Latin America Glioma Treatment Market, by Type, 2021 and 2031

Figure 44: Latin America Glioma Treatment Market Attractiveness Analysis, by Type, 2022–2031

Figure 45: Latin America Glioma Treatment Market, by Treatment, 2021 and 2031

Figure 46: Latin America Glioma Treatment Market Attractiveness Analysis, by Treatment, 2022–2031

Figure 47: Middle East & Africa Glioma Treatment Market Analysis, Value (US$ Mn) Forecast, 2017–2031

Figure 48: Middle East & Africa Glioma Treatment Market Analysis and Forecast, 2021 and 2031

Figure 49: Middle East & Africa Glioma Treatment Market Analysis and Forecast, by Country/Sub-region, 2022–2031

Figure 50: Middle East & Africa Glioma Treatment Market Analysis and Forecast, by Type, 2021 and 2031

Figure 51: Middle East & Africa Glioma Treatment Market Analysis and Forecast, by Type, 2022–2031

Figure 52: Middle East & Africa Glioma Treatment Market Analysis and Forecast, by Treatment, 2021-2031

Figure 53: Middle East & Africa Glioma Treatment Market Analysis and Forecast, by Treatment, 2022–2031

Figure 54: Global Glioma Treatment Market Share Analysis/Ranking, by Company, 2021

Transparency Market Research Plus

Get a free copy if the report you purchased is updated within 90 days

Copyright © Transparency Market Research, Inc. All Rights reserved